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doi:10.1016/j.ejvs.2010.01.002Abstract Objectives: To investigate whether EndoVascular Aneurysm Repair (EVAR) influ-
ences the rate of cardiovascular events (fatal or non-fatal myocardial infarction or stroke)
in patients with abdominal aortic aneurysm (AAA) considered unfit for open repair.
Design: Randomised controlled trial.
Materials: Between 1999 and 2004, 404 patients with large AAA considered unfit for open
repair were randomised to EVAR or no surgical intervention across 33 UK hospitals and followed
until July 2009.
Methods: The Customised Probability Index was used to determine fitness for each patient and
Cox regression was used to compare time to first cardiovascular event between randomised
groups and levels of fitness.
Results: During an average of 2.8 years of follow-up, 67 first cardiovascular events occurred
with a non-significantly higher event rate in the EVAR group compared to the no intervention
group (6.6 versus 5.1 events per 100 person years); adjusted hazard ratio 1.42 [95% CI
0.87e2.34], pZ 0.156. There was no evidence to suggest that the hazard ratio between
randomised groups changed with level of fitness (pZ 0.378).08 846 7307; fax: þ44 208 846 7318.
erial.ac.uk (L.C. Brown).
ty for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
EVAR and Cardiovascular Events in Unfit Patients 397Conclusions: Cardiovascular event rates were high in these unfit patients and medical therapy
was sub-optimal. Events rates were slightly higher in the EVAR group but this was not statis-
tically significant.
ª 2010 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Introduction
The prevalence of abdominal aortic aneurysm (AAA)
increases with age for both sexes1 and there is good
evidence demonstrating an association between the
incidence of cardiovascular disease and the development of
AAA, although the pathology is thought to differ between
the two disease processes.2,3 Possibly the most important
environmental factor associated with the development of
AAA is smoking where the relationship is even stronger than
that seen between smoking and other forms of cardiovas-
cular disease.4e7 Furthermore, a high proportion of
patients with AAA have been shown to have clinically
significant concomitant coronary artery and cerebrovas-
cular disease.8e10
In the early 1990s EndoVascular Aneurysm Repair (EVAR)
was developed specifically for the treatment of patients
who were not considered fit enough to undergo open
surgical repair and, although the use of EVAR is now used
more commonly in fitter patients, it still remains the only
choice of elective intervention for the very unfit. Whether
endovascular intervention is justified in these patients is
currently being tested in the UK EVAR Trial 2 and mid-term
results already have demonstrated that immediate endo-
vascular repair does not provide any benefit in terms of
mortality, quality of life or costs within the first 4 years
after treatment.11 Final long-term results are due for
release in 2010 but the provisional conclusions based on
mid-term data suggest that optimising patient co-morbid-
ities should be prioritised before considering endovascular
repair. However, despite the mid-term results of EVAR Trial
2 demonstrating no benefit, and possible early harm, in
patients undergoing EVAR, it remains a common treatment
choice in these unfit patients.
Unfit patients are vulnerable to a number of co-
morbidities but are at particularly high risk of cardiovas-
cular events. Here, we use data from EVAR Trial 2 to
investigate whether EVAR influences the rate of subsequent
cardiovascular events (defined as fatal or non-fatal
myocardial infarction (MI) or stroke) as it is possible that an
increased rate of cardiovascular events could offset any
potential survival benefit associated with aneurysm repair.
Beyond this, we investigate whether the impact of EVAR
versus no intervention differs across the range of fitness
within the trial.
Materials and methods
The patients
The methods and mid-term results for EVAR Trial 2 have
been published previously.11,12 Patients of both sexes aged
at least 60 years with an aneurysm measuring at least5.5 cm on computed tomography (CT) scan, deemed
anatomically suitable for endovascular repair but anaes-
thetically unfit for an open repair were entered into EVAR
Trial 2 and randomised to either EVAR or no surgical inter-
vention. Full ethical approval for the trial was granted by
the UK North West Multi-centre Research Ethics Committee
(MREC 98/8/26 & 27) and the trials are registered with
international trial number ISRCTN55703451. Patients were
recruited from 33 UK hospitals between September 1999
and August 2004; this includes an additional 66 patients
who were randomised between January and August 2004
who were not included in the planned mid-term analyses
published in 2005.11 Patients are followed up annually by
a dedicated local trial coordinator at each hospital, who
reports prospectively on the events of MI and stroke. All
patients have been flagged at the UK Office for National
Statistics (ONS) for mortality with provision of death
certificates coded according to The International Classifi-
cation of Diseases e 10th Revision (ICD-10) and audited by
a Trial Endpoints Committee. Follow-up data were included
up to the time of analysis in July 2009, an average of
6.8 years after recruitment. Between 2007 and 2009, a trial
auditor visited each hospital site to check the trial case
record forms against the patient notes, to confirm the
occurrence of reported adverse events, and to collect data
on unreported events including MI and stroke. A total of
292 patient notes were available for inspection (72% of all
randomised patients) with the remaining 28% unavailable in
hospital archives or missing from medical records depart-
ments on the dates of audit. The audit confirmed all
previously reported cardiovascular events and also identi-
fied 1 unreported non-fatal stroke; data for this event were
retrieved for inclusion in the main trial database. UK
hospitals work to the World Health Organisation criteria for
these events and therefore events reported in discharge
summaries and hospital notes were included, even when
source documentation was not available at audit. The local
policies on specific levels of enzymes, extent of ECG
disturbance or other neurological criteria were not
recorded but should be consistent within each hospital.
Randomisation was stratified by hospital inferring that
variation in definitions between hospitals should not have
lead to any strong differences between randomised groups.
Definition of cardiovascular events
The primary outcome for the analysis was time from
randomisation to first cardiovascular event defined as
either fatal or non-fatal MI or stroke. In addition, the
numbers of multiple events in patients were summated to
calculate crude overall event rates.
Definition of fatal MI e Primary cause of death after
adjudication of the death certificate assigned under ICD-10
myocardial infarction codes I210eI238.
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from the coordinator at the participating hospital or any
mention of ICD-10 codes I210eI238 on the death certificate
providing they were not attributed as the original under-
lying cause of death. In these cases, the date of death was
used as the date of event and the events were reviewed by
two independent assessors without knowledge of rando-
mised group (authors JTP and LCB).
Definition of fatal stroke e Primary cause of death on
death certificate assigned under cerebrovascular events
leading to stroke ICD-10 codes I160eI164.
Definition of non-fatal stroke e Any report of a non-
fatal stroke from the coordinator at the participating
hospital or any mention of ICD-10 codes I160eI164 on the
death certificate classified according to the same criteria
used for non-fatal MI.
Assessment of patient fitness
Previous research using data from EVAR Trial 1 (where fit
patients were randomised to receive either open or endo-
vascular repair) has used the Customised Probability Index
(CPI) to investigate the role of fitness in patients under-
going AAA repair.13e15 A slightly modified version of the
score was used based upon the data available in the EVAR
Trials database as described previously.13 In brief, the CPI is
a validated prognostic score for operative mortality after
open AAA repair but for this analysis it was used as an
indicator of fitness rather than a prognostic indicator for
survival after open repair. It includes components for
cardiac, respiratory and renal function as well as use of
beta-blockade or statins. Possible scores range from 25 in
the most fit to þ57 in the least fit with higher scores
indicating a higher risk of operative death after AAA repair.
This modified score was applied to the patients in EVAR
Trial 2 but split into tertiles (thirds) for the purpose of
presentation. For 30 of the 404 patients, one score
component was missing and linear regression was used to
impute the missing component based upon CPI variables in
the 373 patients with complete data. For one patient, more
than one component was missing and this patient was
excluded from the analysis investigating the impact of EVAR
across the fitness spectrum.
Statistical analysis
The analysis was conducted according to a pre-defined
statistical analysis plan and performed using Stata version 10
(Stata Corporation, Texas, USA). All patients were analysed
within their randomised group according to the intention-to-
treat principle. Given that some patients were still under
standard annual follow-up and some had died or been lost to
follow-up, the timing of events and censoring of patients was
pre-defined according to the following rules.
For patients with an event recorded since
randomisation:
- if the patient had a baseline/follow-up appointment or
had been audited within 18 months prior to a first
recorded event, then the event was defined as the first
event.- If the patient had a baseline/follow-up appointment or
had been audited more than 18 months prior to the
event, then it could not be assumed that this was the
first event and the patients were censored without an
event on the date last seen or audited. This removed
events in a small number of patients (nZ 4) who were
not seen for at least 18 months and then had a reported
cardiovascular event.
For patients without any event recorded, censoring
occurred at the latest of these dates:
- for patients who are alive, the date of last follow-up
appointment or the date of audit.
- for patients who are dead, the date of death (without
mention of MI or stroke cause) was used providing the
death occurred within 18 months after the last follow-
up or date of audit. For patients dying more than
18 months after their last follow-up or date of audit,
the date of follow-up or audit was used for censoring.
Cox regression modelling was used to compare time to
first cardiovascular event between randomised groups.
Crude hazard ratios were presented as well as ones
adjusted for baseline age, sex, AAA diameter, body mass
index, systolic blood pressure, serum total cholesterol,
history of cardiac disease (defined as previous MI, angina,
cardiac revascularisation, cardiac valve disease, significant
arrhythmia or uncontrolled congestive cardiac failure),
mean Ankle Brachial Pressure Index, Forced Expiration
Volume in 1 s, log (serum creatinine), statin use, aspirin
use, smoking status (current, past or never) and diabetes.
Adjustment was performed using a propensity score
developed from a logistic regression model using these
covariates to predict randomised group. The propensity
score was available for patients with complete data.
54 patients without a prognostic score due to missing
covariates were incorporated into the adjusted model using
the missing indicator method.16 KaplaneMeier methods
were used to display curves for survival without a cardio-
vascular event between randomised groups and fitness
tertile groups.
To investigate whether the hazard ratio between EVAR
and no intervention differed with fitness, a test for inter-
action was performed between randomised group and CPI
score. The CPI score was included in the Cox model in
continuous format but data were presented within tertile
groups to indicate the magnitude of any effect.Results
Between September 1999 and August 2004, a total of 404
patients were randomised, 197 to EVAR and 207 to no
intervention. The baseline characteristics were very similar
between randomised groups and with those published
previously.11 The mean (SD) age and AAA diameter were
77 (6) years and 6.7 (1.0) cm respectively with 86% male.
A large proportion of patients had a history of previous
cardiac disease with a non-significantly higher percentage
in the no intervention group (74%) when compared with the
EVAR group (67%); Chi-squared test, pZ 0.128. The use of
Table 1 Types of first cardiovascular events by rando-
mised group within EVAR Trial 2.
Event type EVAR
NZ 197 patients
No intervention
NZ 207 patients
Fatal myocardial
infarctiona
14 20
Non-fatal myocardial
infarctionb
10 2
Fatal strokea 5 3
Non-fatal strokeb 7 6
Total events 36 31
a All 42 fatal events were ascertained from the death certif-
icates as the primary cause of death.
b For the 25 non-fatal events, 11 were ascertained from
standard follow-up or audit with enzymal/ECG/neurology
reports, 7 were ascertained from standard follow-up or audit
without enzymal/ECG/neurology reports and 7 were ascer-
tained from death certificates without MI or stroke as under-
lying cause of death.
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only 57% and 42% of patients being treated with aspirin and
statins respectively but usage was not different between
randomised groups. Data were not available on other fitness
optimisation methods. The mean (SD) CPI score was
10.0 (11.3) with little difference between randomised
groups; 10.9 (12.0) in the EVAR group and 9.2 (10.5) in the
no intervention group. This was significantly higher than the
CPI scores measured in the EVAR 1 Trial which have been
reported previously; mean (SD)Z 3.6 (9.3).13 The CPI
scores were approximately normally distributed as can be
seen from the histogram in Fig. 1. Compliance with
randomised treatment was moderate (79%). In the group
randomised to EVAR, 17 patients did not have an AAA repair
and 5 had an elective or emergency open repair. In the
group randomised to no intervention, 12 had an elective
open repair and 51 had an elective EVAR at some point
during follow-up.
Patients were followed for an average of 6.8 years after
recruitment (unconditional follow-up) with only 2 patients
lost to follow-up. There was a high attrition of follow-up
due to patients being censored at death and time after
non-fatal events being excluded (conditional follow-up).
Thus, a total of 67 first cardiovascular events occurred
during an average of 2.8 years of conditional follow-up and
a breakdown of the type of events is given in Table 1.
Of these 67 patients, 2 went on to have a second event and
1 had a third event generating a total of 70 events in an
average of 2.8 years of follow-up; crude overall rate
6.1 [95% CI 4.7e7.6] events per 100 person years. In the
EVAR group, 3 cardiovascular events were reported before
the EVAR procedure and 10 occurred within 30 days of the
EVAR, with the remaining 23 occurring more than 30 days
after EVAR. In the no intervention group, 9 events occurred
after AAA repair in the 63 patients having aneurysm repair
against protocol (none within 30 days). For the 319 patients
complying with their randomised allocation, 33 (19%)
patients in the EVAR group and 22 (15%) patients in the no60
40
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0
Frequency
-20 -15 -10 -5 0 5 10 15 20 25 30 35 40 45
Imputed CPI score
Most fit Moderately fit    Least fit
Number 138 141 124
Mean -2.1 10.2 23.3
Figure 1 Histogram of CPI scores for 403 patients in EVAR
Trial 2 coloured coded into green, orange and red for the most,
moderately and least fit tertiles.intervention group experienced a cardiovascular event
during follow-up; adjusted Cox hazard ratio 1.07 [95% CI
0.60e1.91].
Table 2 presents the results of Cox regression modelling
between randomised groups and Fig. 2 shows the Kaplane
Meier estimates up to the first 6 years after randomisation.
The patients in the EVAR group experienced a higher rate of
cardiovascular events, but this did not reach statistical
significance, pZ 0.156. The CPI score includes a compo-
nent for cardiac disease so it was unsurprising that the rate
of cardiovascular events tended to increase as fitness
deteriorated (Fig. 3) but the test of interaction between
randomised group and CPI score was non-significant with no
particular trend for the Cox regression hazard ratios across
the tertile groups (pZ 0.378, Table 2).
The overall event rate was compared to that seen in
EVAR Trial 1 of 1252 patients comparing EVAR with open
repair in patients considered fit for open repair, where
a total of 171 cardiovascular events had occurred during an
average of 4.4 years of follow-up (crude rate 3.1 [95% CI
2.7e3.6] events per 100 person years). Unsurprisingly,
patients in the EVAR 2 trial experienced a significantly
higher rate of cardiovascular events than those in EVAR
Trial 1; crude Cox regression hazard ratio 1.77 [95% CI
1.33e2.36] p< 0.001.
Discussion
Patients with aortic aneurysm are known to be at greater
risk of mortality than the age and sex-matched pop-
ulation.2,17 Much of this increase is thought to be from
cardiovascular disease and it has been shown to persist
beyond repair of the aneurysm.17 As far as we are aware,
this is the first published analysis of fatal and non-fatal
cardiovascular events in unfit patients with AAA, although
numerous studies have demonstrated a high cardiovascular
event rate in patients with any kind of peripheral vascular
disease and quote a 5-year risk of approximately 25%.18
Much of the literature on cardiovascular outcomes
Table 2 Results from Cox regression model comparing time to first cardiovascular event between EVAR and no intervention for
all patients and within tertiles of fitness in EVAR Trial 2.
Fitnessa
(CPI score missing
in 1 patient)
EVAR
NZ 197
Number of
events/patients
(rate per 100
person years)
No intervention
NZ 207
Number of
events/patients
(rate per 100
person years)
Crude
hazard
ratio
[95% CI]
p-value
Adjusted
hazardb
ratio
[95% CI]
p-value
p-Value from
test of interaction in
adjustedb model
All patients
NZ 404
36/197
(6.6)
31/207
(5.1)
1.31
[0.81e2.12]
0.272
1.42
[0.87e2.34]
0.156
Not applicable
Good fitness
NZ 138
11/62
(5.8)
9/76
(3.5)
2.01
[0.80e5.07]
1.98
[0.75e5.24]
pZ 0.378
CPI score included in
continuous format
Moderate fitness
NZ 141
11/65
(5.8)
14/76
(7.1)
0.83
[0.38e1.84]
1.05
[0.45e2.42]
Poor fitness
NZ 124
14/69
(8.6)
8/55
(5.3)
1.65
[0.69e3.93]
1.61
[0.67e3.87]
a Customised Probability Index (CPI) score used to classify patients into tertile groups of fitness but included in the adjusted Cox model
in continuous format as an interaction term with randomised group.
b adjusted for age, sex, AAA diameter, body mass index, systolic blood pressure, cholesterol, cardiac disease (previous history of any of
the following: myocardial infarction, angina, severe valve disease, significant arrhythmia, uncontrolled congestive cardiac failure),
ankle brachial pressure index (mean of both legs), Forced expiration volume in 1 s, log(creatinine), statin use, aspirin use, smoking
status and diabetes. Missing indicator method used to include 54 patients without a complete set of covariates.
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terms of relative and absolute percentage risks rather than
rates per 100 person years so it is difficult to compare
directly the results presented here with those in the
general or high risk population. We have only identified one
previous study which reported on cardiovascular event
rates during long-term follow-up of (presumably fit)
patients undergoing open aneurysm repair, where Kaplane
Meier estimates at 3 and 5 years were 10.3% and 14.9%
respectively.19 The rates observed in the EVAR 2 trial were
almost twice this, even though most of the interventions
used the less invasive endovascular technique. Similarly,
the rates observed in the EVAR 2 trial were almost twice
those in EVAR Trial 1, where fit patients were randomised to
either EVAR or open repair.
Use of optimal medical therapy was poor in the UK EVAR
Trials, particularly in EVAR Trial 2 where use of anti-platelet
and statin therapy should have been prescribed to all
patients, unless contraindicated. Overall, only 47% of0 2 4 6
Time from randomisation (years)
Proportion
surviving
without a
cardiovascular
event 
Number at risk
EVAR 197            117         56               14        
No intervention 207            127             67               16   
100
75
50
25
0
EVAR
No intervention 
Estimates (%):      EVAR No intervention
6 months 95 [90-97] 97 [93-98]
24 months 89 [83-93] 91 [85-94]
48 months 76 [67-83] 81 [73-87]
Figure 2 KaplaneMeier estimates for time to first cardio-
vascular event stratified by randomised group.patients had baseline systolic blood pressure below the
recommended maximum level of 140 mmHg and it seems
likely that the high cardiovascular event rates seen in these
patients could be reduced simply by a more rigorous
application of medical therapy. In addition, outcomes
might have been improved if referral to cardiac, renal and
respiratory specialists had been more rigorously imple-
mented. In some cases, optimisation of respiratory function
may have lead to an improved prognosis in these sick
patients as demonstrated in other research.20
As anticipated, Table 2 and Fig. 3 demonstrate that the
rate of cardiovascular events tends to increase as patient
fitness deteriorates but the non-significant test of interac-
tion with randomised group suggests that the impact of
EVAR relative to no intervention is not being influenced
strongly by patient fitness. All these patients have been
deemed unfit for open repair and represent the extreme0 2 4 6
Time from randomisation (years) 
Most fit
Moderately fit
Least fit
Proportion 
surviving
without a 
cardiovascular 
event 
100 
75 
50 
25 
0
Figure 3 KaplaneMeier estimates for time to first cardio-
vascular event coloured coded into green, orange and red for
the most, moderately and least fit tertiles.
EVAR and Cardiovascular Events in Unfit Patients 401end of the spectrum of fitness with numerous other non-
cardiovascular factors influencing their classification as
unsuitable for open repair. In addition, trial protocol
guidelines recommended that any patient with myocardial
infarction or new onset of angina within the previous
3 months should not be considered for entry into the trial.
We acknowledge that there are limitations to this study.
First, it is possible that some non-fatal MI and stroke events
have not been reported if patients were referred to other
hospitals for treatment. Second, the ascertainment of
non-fatal events from death certificates is unconventional,
but allowed inclusion of a further 7 non-fatal events (10% of
the total) that occurred between last follow-up and death.
Third, clinical confirmation of non-fatal events according to
World Health Organisation (WHO) criteria was available for
just 44% of all events and it is possible that the rates pre-
sented here are an over-estimate of the event rate defined
according to WHO standards. However, the impact of these
limitations is reduced by the randomised nature of the study
design and the analysis of patients according to the inten-
tion-to-treat principle. Conversely, the overall compliance
with randomised group was only moderate in this trial (79%)
with 30% of patients in the no intervention group eventually
crossing over to have elective AAA repair. Given that growth
of the AAA as well as changes in the fitness status of patients
after randomisation would have considerable bearing on the
decision to intervene for the aneurysm, the per protocol
results that are presented here are likely to be biased and
therefore are difficult to interpret. Nevertheless, they
confirm the intention-to-treat results with no significant
difference in event rates demonstrated between compliant
groups. Interestingly, there were no cardiovascular events
within 30 days of delayed aneurysm repair (nZ 63), against
protocol, in the no intervention group as compared to 10
within 30 days of EVAR in the group randomised to EVAR. This
could reflect an improvement in fitness in the patients with
delayed AAA repair but also, it is possible that these patients
came from the fitter end of the spectrum thus allowing
consideration of AAA repair more readily.
In this study, we have investigated the impact of EVAR on
cardiovascular event rates in unfit patients and shown that
there is only weak evidence to suggest a higher rate after
EVAR than surveillance alone. Moreover, Fig. 2 demonstrates
that most of the difference between groups was evident
after 4 years of follow-up, when there were few patients
remaining under follow-up. Nevertheless, these results lend
weight to the conclusions of our earlier publication,11 where
we suggested that optimisation of co-morbidites and
improvement of patient fitness should remain the goal in
these patients before aneurysm repair is considered.
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